On December 6, 2025, Onconetix, Inc. amended its license agreement with Labcorp, allowing Labcorp to conduct a new validation study for Proclarix and pay up to $300,000 for milestone-based support; no royalties are due for the study.
AI Assistant
ONCONETIX INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.